Associated Banc Corp reduced its holdings in Bristol-Myers Squibb (NYSE:BMY) by 1.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 128,032 shares of the biopharmaceutical company’s stock after selling 1,756 shares during the quarter. Associated Banc Corp’s holdings in Bristol-Myers Squibb were worth $8,098,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Delphi Private Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $108,000. NuWave Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $119,000. Horan Capital Advisors LLC. bought a new stake in shares of Bristol-Myers Squibb in the third quarter valued at about $122,000. Prentiss Smith & Co. Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $143,000. Finally, Santori & Peters Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $144,000. 71.49% of the stock is currently owned by institutional investors.
Several equities research analysts recently weighed in on the stock. Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, February 16th. Jefferies Group set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 26th. TheStreet cut shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. DZ Bank cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, Argus reiterated a “buy” rating and issued a $66.43 target price (down previously from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, March 21st. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $63.68.
Shares of Bristol-Myers Squibb opened at $52.30 on Wednesday, according to MarketBeat Ratings. The stock has a market cap of $84.77 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 1.30 and a beta of 0.99. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.52 and a quick ratio of 1.39. Bristol-Myers Squibb has a 12 month low of $51.74 and a 12 month high of $52.24.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. The firm had revenue of $5.19 billion during the quarter, compared to analysts’ expectations of $5.25 billion. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.84 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb will post 3.41 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date of this dividend was Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.
In other news, Director Dinesh C. Paliwal acquired 4,770 shares of the company’s stock in a transaction dated Monday, April 30th. The stock was bought at an average price of $52.40 per share, with a total value of $249,948.00. Following the completion of the acquisition, the director now owns 8,027 shares in the company, valued at approximately $420,614.80. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.12% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.